BS Summary: This article contains 3 faulty reasoning types, including Framing Effect and Biased Writer Voice, with Optimism Bias as the most egregious example at 34.2% saturation with 39 hits. Analysis detected 87 faulty-reasoning hits from 114 analyzed words, generating a BS Score of 23.2% and a BS Rank of 13% (24,010 of 27,321 articles). This article is better (less manipulative) than 87.90% of the article peer group.
BioNTech on Monday named Guido Oelkers, formerly the leader of the Swedish biopharma company Sobi, as its new CEO, as the Covid-19 vaccine developer continues its shift to oncology.
Oelkers will replace Ugur Sahin as CEO.
In March, BioNTech announced that Sahin and his cofounder and wife Özlem Türeci, the company’s chief medical officer, would depart the company to lead a new biotech focused on developing mRNA medicines.
Oelkers, who has worked in biopharma for more than 30 years, will start by Feb. 1, 2027, the company said.
He said that he would continue BioNTech’s work to be a global company with multiple approved medicines by 2030.
Speakers
2speakers60%attributed speech46writer words
Selected voice
100%flagged-word coverageGuido Oelkers
19 attributed words28% of attributed speech0% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.